News Headlines

  1. InflaRx Initiates Phase II Clinical Trial With IFX-1 In ANCA-Associated Vasculitis With First Patient Dosing
    10/30/2018

    InflaRx N.V.(Nasdaq: IFRX), a biopharmaceutical company developing innovative therapeutics to treat devastating inflammatory diseases by targeting the complement system, a key component of the innate immune system, today announced that the first patient has been dosed in a phase II study to determine the safety and efficacy of IFX-1, a first-in-class anti-human complement factor C5a antibody, in patients with ANCA-associated vasculitis (AAV).

  2. ContraVir Pharmaceuticals Completes Final Cohort Dosing In CRV431 Drug-Drug Interaction Study
    10/30/2018

    ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus (“HBV”), today announced that it has completed dosing of the last cohort of healthy subjects for its CRV431 drug-drug interaction (“DDI”) study.

  3. Mustang Bio Announces Updates On CAR T Cell Therapy Clinical Trials With City Of Hope
    10/30/2018

    Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology and gene therapies for rare diseases, today announced that a Phase 1 clinical trial evaluating the safety and effectiveness of intraventricular delivery of CAR T cells to the brains of patients with HER2-positive breast cancer with brain metastases has been initiated.

  4. Cymabay Announces The Initiation Of The Seladelpar Global Phase 3 Registration Study (ENHANCE) For The Treatment Of Primary Biliary Cholangitis And Additional Corporate Updates
    10/30/2018

    CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced that the company has initiated the seladelpar Phase 3 registration study for the treatment of Primary Biliary Cholangitis (PBC).

  5. Advarra Completes Integration, Renews Focus On Efficient Research Compliance Services
    10/25/2018

    Advarra, the premier provider of IRB, IBC and research quality and compliance consulting services in North America, has completed all integration activities.

  6. Fibrocell Receives Guidance From FDA On Phase 3 Clinical Trial Design For FCX-007
    10/25/2018

    Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced completion of a Type C meeting with the U.S. Food and Drug Administration (FDA) to discuss the design of a Phase 3 clinical trial protocol of FCX-007, the Company’s gene therapy candidate for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). 

  7. Moleculin Announces Positive Data On WP1066 In Pre-Clinical Trials
    10/25/2018

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that investigators at Emory University will present animal model data supporting the potential of WP1066 to treat pediatric brain tumors at the upcoming Society for Neuro-Oncology Annual Scientific Meeting.

  8. Santhera Announces Start Of Phase Ib/IIa Trial With POL6014 In Patients With Cystic Fibrosis
    10/24/2018

    Santhera Pharmaceuticals (SIX: SANN) announces the start of a Phase Ib/IIa multiple ascending dose (MAD) trial with POL6014 in patients with cystic fibrosis (CF).

  9. Celsion Announces Progression-Free Survival Data From GEN-1 Phase I Immuno-Oncology Study Of Patients With Stage III/IV Ovarian Cancer
    10/24/2018

    Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced results from its dose escalating Phase IB OVATION I trial evaluating neoadjuvant chemotherapy (NAC) treatment for six cycles and GEN-1 given weekly for a total of eight doses prior to interval debulking surgery in newly diagnosed patients with Stage III/IV ovarian cancer. 

  10. NeoGenomics Signs Definitive Agreement To Acquire Genoptix
    10/23/2018

    NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has entered into a definitive agreement to acquire Genoptix, Inc. for $125 million in cash and 1 million shares of NeoGenomics common stock.